Skip to main content
SpringerLink
Log in

Mature B-Cell Neoplasms

  • Chapter
  • First Online:
Practical Oncologic Molecular Pathology

Part of the book series: Practical Anatomic Pathology ((PAP))

  • 1719 Accesses

Abstract

Understanding the pathogenesis of mature B-cell neoplasms has been the focus of research and clinical investigations in the past decades and significantly enhanced by the advancement of molecular technology. Mature B-cell neoplasms comprise several different entities, whose diagnostic classification involves clinical, morphological, immunophenotypic, and molecular features. In the past, determination of clonality, detection of cytogenetic abnormalities, and identification of recurrent mutations can help to confirm the clonal nature of a disease and disease subclassification. High-throughput genetic technologies, such as next-generation sequencing, have made significant contributions in new diagnostic tools, refinement of WHO classification of lymphoid neoplasms, and identification of new therapeutic targets. This chapter provides a general overview of the clinically relevant molecular tests available for neoplasms of mature B cells and presents case studies to highlight practical indications and utilization of molecular tests in B-cell neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67(11):923–31.

    Article  CAS  PubMed  Google Scholar 

  2. Sioutos N, Bagg A, Michaud GY, Irving SG, Hartmann DP, Siragy H, et al. Polymerase chain reaction versus southern blot hybridization. Detection of immunoglobulin heavy-chain gene rearrangements. Diagn Mol Pathol. 1995;4(1):8–13.

    Article  CAS  PubMed  Google Scholar 

  3. van Krieken JH, Langerak AW, Macintyre EA, Kneba M, Hodges E, Sanz RG, et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 concerted action BHM4-CT98-3936. Leukemia. 2007;21(2):201–6.

    Article  PubMed  CAS  Google Scholar 

  4. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317.

    Article  PubMed  Google Scholar 

  5. Hoeve MA, Krol AD, Philippo K, Derksen PW, Veenendaal RA, Schuuring E, et al. Limitations of clonality analysis of B cell proliferations using CDR3 polymerase chain reaction. Mol Pathol. 2000;53(4):194–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Taylor JM, Spagnolo DV, Kay PH. B-cell target DNA quantity is a critical factor in the interpretation of B-cell clonality by PCR. Pathology. 1997;29(3):309–12.

    Article  CAS  PubMed  Google Scholar 

  7. Zhou XG, Sandvej K, Gregersen N, Hamilton-Dutoit SJ. Detection of clonal B cells in microdissected reactive lymphoproliferations: possible diagnostic pitfalls in PCR analysis of immunoglobulin heavy chain gene rearrangement. Mol Pathol. 1999;52(2):104–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Elenitoba-Johnson KS, Bohling SD, Mitchell RS, Brown MS, Robetorye RS. PCR analysis of the immunoglobulin heavy chain gene in polyclonal processes can yield pseudoclonal bands as an artifact of low B cell number. J Mol Diagn. 2000;2(2):92–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Groenen PJ, Langerak AW, van Dongen JJ, van Krieken JH. Pitfalls in TCR gene clonality testing: teaching cases. J Hematop. 2008;1(2):97–109.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia. 2012;26(10):2159–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Boer A, Tirumalae R, Bresch M, Falk TM. Pseudoclonality in cutaneous pseudolymphomas: a pitfall in interpretation of rearrangement studies. Br J Dermatol. 2008;159(2):394–402.

    Article  CAS  PubMed  Google Scholar 

  12. Evans PA, Pott C, Groenen PJ, Salles G, Davi F, Berger F, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 concerted action BHM4-CT98-3936. Leukemia. 2007;21(2):207–14.

    Article  CAS  PubMed  Google Scholar 

  13. Langerak AW, Molina TJ, Lavender FL, Pearson D, Flohr T, Sambade C, et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2007;21(2):222–9.

    Article  CAS  PubMed  Google Scholar 

  14. Krejci O, Prouzova Z, Horvath O, Trka J, Hrusak O. Cutting edge: TCR delta gene is frequently rearranged in adult B lymphocytes. J Immunol. 2003;171(2):524–7.

    Article  CAS  PubMed  Google Scholar 

  15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.

    Article  PubMed  Google Scholar 

  16. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

    Article  CAS  PubMed  Google Scholar 

  17. Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312(21):2265–76.

    Article  PubMed  CAS  Google Scholar 

  18. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-then and now. Am J Hematol. 2016;91(3):330–40.

    Article  CAS  PubMed  Google Scholar 

  19. Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16(11):684–701.

    Article  CAS  PubMed  Google Scholar 

  20. Crassini K, Stevenson WS, Mulligan SP, Best OG. Molecular pathogenesis of chronic lymphocytic leukaemia. Br J Haematol. 2019;186(5):668–84.

    Article  PubMed  Google Scholar 

  21. Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, et al. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica. 2018;103(12):2069–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.

    Article  CAS  PubMed  Google Scholar 

  23. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001;97(7):2098–104.

    Article  CAS  PubMed  Google Scholar 

  24. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673–82.

    Article  CAS  PubMed  Google Scholar 

  26. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25(3):489–97.

    Article  CAS  PubMed  Google Scholar 

  27. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28–40.

    Article  CAS  PubMed  Google Scholar 

  28. Guieze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood. 2015;126(18):2110–7.

    Article  CAS  PubMed  Google Scholar 

  29. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995–1004.

    Article  CAS  PubMed  Google Scholar 

  30. Rozovski U, Keating MJ, Estrov Z. Why is the immunoglobulin heavy chain gene mutation status a prognostic Indicator in chronic lymphocytic Leukemia? Acta Haematol. 2018;140(1):51–4.

    Article  CAS  PubMed  Google Scholar 

  31. Rosenquist R, Ghia P, Hadzidimitriou A, Sutton LA, Agathangelidis A, Baliakas P, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31(7):1477–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.

    Article  PubMed  Google Scholar 

  33. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47–52.

    Article  PubMed  CAS  Google Scholar 

  34. Malcikova J, Smardova J, Rocnova L, Tichy B, Kuglik P, Vranova V, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114(26):5307–14.

    Article  CAS  PubMed  Google Scholar 

  35. Yu L, Kim HT, Kasar S, Benien P, Du W, Hoang K, et al. Survival of Del17p CLL depends on genomic complexity and somatic mutation. Clin Cancer Res. 2017;23(3):735–45.

    Article  CAS  PubMed  Google Scholar 

  36. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–7.

    Article  CAS  PubMed  Google Scholar 

  37. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.

    Article  CAS  PubMed  Google Scholar 

  38. Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016;7(4):4598–610.

    Article  PubMed  Google Scholar 

  39. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Puente XS, Bea SR, Villamor N, Gutierrez-Abril J, Martin-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519–24.

    Article  CAS  PubMed  Google Scholar 

  42. Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Dohner K, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123(21):3247–54.

    Article  CAS  PubMed  Google Scholar 

  43. Chiaretti S, Marinelli M, Del Giudice I, Bonina S, Piciocchi A, Messina M, et al. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. Leuk Lymphoma. 2014;55(12):2785–92.

    Article  CAS  PubMed  Google Scholar 

  44. Winkelmann N, Rose-Zerilli M, Forster J, Parry M, Parker A, Gardiner A, et al. Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica. 2015;100(6):e237–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108–17.

    Article  CAS  PubMed  Google Scholar 

  47. Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, et al. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(4):920–8.

    Article  PubMed  Google Scholar 

  48. Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with Ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2020:JCO2000979.

    Google Scholar 

  49. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367(9):826–33.

    Article  CAS  PubMed  Google Scholar 

  50. Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, et al. Genomic landscape of Waldenstrom macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, et al. Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia. Blood Adv. 2018;2(21):2937–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, et al. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018;93(2):187–94.

    Article  CAS  PubMed  Google Scholar 

  53. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, Scheepstra C, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, et al. MYD88 L265P mutation in lymphoid malignancies. Cancer Res. 2018;78(10):2457–62.

    Article  CAS  PubMed  Google Scholar 

  55. Varettoni M, Zibellini S, Arcaini L, Boveri E, Rattotti S, Pascutto C, et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood. 2013;122(13):2284–5.

    Article  CAS  PubMed  Google Scholar 

  56. Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol. 2019;12(1):118.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  57. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Huet S, Xerri L, Tesson B, Mareschal S, Taix S, Mescam-Mancini L, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J. 2017;7(4):e555.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020;4(13):2927–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Tamaru J, Hummel M, Zemlin M, Kalvelage B, Stein H. Hodgkin’s disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood. 1994;84(3):708–15.

    Article  CAS  PubMed  Google Scholar 

  63. Fromm JR, Wood BL. A six-color flow cytometry assay for immunophenotyping classical Hodgkin lymphoma in lymph nodes. Am J Clin Pathol. 2014;141(3):388–96.

    Article  PubMed  Google Scholar 

  64. Wu D, Wood BL, Fromm JR. Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma. Methods Mol Biol. 2013;971:27–47.

    Article  CAS  PubMed  Google Scholar 

  65. Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015:368–77.

    Article  PubMed  Google Scholar 

  66. Cohen JA, Bomben R, Pozzo F, Tissino E, Harzschel A, Hartmann TN, et al. An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. “Cancers (Basel). 2020;12(4):894.

    Google Scholar 

  67. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Scheffold A, Stilgenbauer S. Revolution of chronic lymphocytic Leukemia therapy: the chemo-free treatment paradigm. Curr Oncol Rep. 2020;22(2):16.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Molecular diagnostics in chronic lymphocytic leukemia – pathogenetic and clinical implications. Leuk Lymphoma. 2008;49(5):864–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Health, Danville, PA, USA

    Yi Ding

Authors
  1. Yi Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi Ding .

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine, Geisinger Health, Danville, PA, USA

    Yi Ding

  2. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Linsheng Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ding, Y. (2021). Mature B-Cell Neoplasms. In: Ding, Y., Zhang, L. (eds) Practical Oncologic Molecular Pathology. Practical Anatomic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-73227-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-73227-1_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-73226-4

  • Online ISBN: 978-3-030-73227-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation